In this webinar, Dr Greg Keir, Respiratory and Sleep Physician, provides an overview on the recent updates in treatment and management for pulmonary fibrosis (PF) including immunosuppressant medication and recent advances in anti-fibrotic medications. Pulmonary fibrosis is a progressive lung disease marked by scarring (fibrosis) that makes breathing difficult. It has multiple causes, including environmental exposures (asbestos, silica), autoimmune diseases (rheumatoid arthritis, scleroderma), and unknown origins, which is known as idiopathic pulmonary fibrosis (IPF). IPF typically affects older adults, especially past smokers. Symptoms include shortness of breath, dry cough, and fatigue. Diagnosis involves CT scans, lung function tests, and sometimes biopsies. While no cure exists, treatments like nintedanib and pirfenidone can slow progression. Pulmonary rehabilitation, oxygen therapy, and clinical trials also support symptom management. Early diagnosis is key to improving outcomes and quality of life.
Idiopathic pulmonary fibrosis (IPF) treatment focuses on slowing lung scarring and managing symptoms. Two key anti-fibrotic medications nintedanib and pirfenidone are proven to reduce the rate of lung function decline. While both are similarly effective, they differ in side effects: nintedanib may cause diarrhea and nausea, while pirfenidone can lead to sun sensitivity and appetite loss. Side effects are often manageable with dose adjustments and food intake. Symptom relief includes pulmonary rehabilitation, tailored exercise and education programs, and oxygen therapy for low blood oxygen levels. A holistic, personalised approach improves quality of life and supports long-term lung health.
Pulmonary fibrosis treatment extends beyond medication to include oxygen therapy, cough management, and emotional support. Oxygen is prescribed when blood oxygen levels drop, not just for breathlessness, but to protect the heart and improve long-term survival. Persistent dry cough, a common symptom, may be managed with medications, reflux treatment, or cough syrups. Pulmonary rehabilitation and Peer Connect programs offer tailored exercise, education, and emotional support. These holistic approaches improve quality of life, reduce anxiety, and help patients manage breathlessness and fatigue.
Was this page helpful?
Good job! Please give your positive feedback
How could we improve this post? Please Help us.
